Bridger Management, LLC Incyte Corp Transaction History

Bridger Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $30.8 Million - $40.7 Million	-404,650 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $4.98 Million - $6.03 Million	61,700 Added 17.99%	404,650 $35.2 Million
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $6.21 Million - $9.12 Million	-83,758 Reduced 19.63%	342,950 $35.7 Million
Q1 2020 May 15, 2020	BUY	$63.18 - $85.97 $27 Million - $36.7 Million	426,708 New	426,708 $31.2 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $37.9 Million - $52.2 Million	-622,152 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $28.7 Million - $35.8 Million	306,890 Added 97.34%	622,152 $58.9 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $34.4 Million - $43.6 Million	315,262	315,262 $36.8 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Bridger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridger Management, LLC with notifications on news.